News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Moomoo Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article focuses on the enterprise value to revenue forward metric for Werewolf Therapeutics, Inc. (NASDAQ: HOWL). It appears to be a financial data point presented by TradingView, indicating a specific valuation ratio for the pharmaceutical company. The content itself is minimal, primarily highlighting …
Werewolf Therapeutics reported that as of June 30, their cash and cash equivalents stood at $22 million. This financial update indicates the company's liquid assets at the end of the second quarter.
Werewolf Therapeutics (HOWL) reported Q2 2026 financial results, including $21.0 million in collaboration revenue and $3.7 million net income, primarily from selling its JZP898 program. The company also announced repayment of its loan with K2 HealthVentures and is exploring strategic alternatives, with updates expected …
Werewolf Therapeutics, Inc. reported a significant turnaround in 2Q 2026, recognizing $21 million in collaboration revenue and achieving a net income of $3.67 million, or $0.08 diluted EPS, compared to a net loss in the prior year. This improvement was driven by the upfront …
Werewolf Therapeutics (Nasdaq: HOWL) announced its financial results for the second quarter ended June 30, 2026, including a net income of $3.7 million, a significant improvement from a net loss in the prior year. The company's cash and cash equivalents stood at $22.0 million, …
Werewolf Therapeutics Inc (HOWL) has a risk assessment score of 1.54, ranking 285 out of 384 in the Biotechnology & Medical Research industry. The company's beta value is 0.32, indicating it tends to underperform during upward markets but experiences smaller declines during downward trends. …
Werewolf Therapeutics (HOWL) reported Q2 2026 earnings on July 31, 2026, with an EPS of $0.08, significantly beating analysts' consensus of -$0.28. The company's revenue for the quarter was $21 million, meeting the consensus estimate. Werewolf Therapeutics' next Q3 earnings are estimated for August …
This article provides a comprehensive stock analysis of Werewolf Therapeutics Inc (HOWL) by TradingKey, detailing its fundamentals, valuation, and market performance. Key insights indicate healthy fundamentals, high growth potential, and a 'Buy' rating from multiple analysts despite an expected medium-term downward trend. The analysis …
This article provides an overview of Werewolf Therapeutics Inc (HOWL)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and lists basic financial data such as its market capitalization and current stock price. …
This article provides an overview of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) financials on TradingView. It indicates that the market was closed with no trades. The content primarily outlines the navigation structure and available financial data categories on the TradingView platform for this company.
Werewolf Therapeutics Inc (HOWL) currently has a valuation score of 7.06, placing it 270 out of 386 in the Biotechnology & Medical Research industry. Its P/E ratio is -0.36, which is significantly below its recent high but above its recent low. The company has …
This article provides a financial health analysis of Werewolf Therapeutics Inc (HOWL), ranking its financial score at 6.80 within the Biotechnology & Medical Research industry. It indicates robust financial status but low operating efficiency. The analysis highlights that relevant data for various financial dimensions …
HOWL stock, tied to Werewolf Therapeutics, Inc., is gaining attention in the context of its latest investor materials and general market sentiment. The company, a Nasdaq-listed biotech, focuses on next-generation immunotherapies, and its stock performance is primarily driven by its pipeline depth, trial timing, …
Werewolf Therapeutics (HOWL) stock is trading based on recent clinical trial updates and financial results. The company reported increased revenue from collaborations but also higher R&D expenses, leading to a net loss of $60 million in fiscal 2024. Despite this, a cash reserve of …
Search by ticker symbol or company name and select a result to open its chart.